Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism

American Journal of Hematology

Volumn 71, Issue 4, 2002, Pages 285-290

  Folsom, Aaron R ^a   Cushman, Mary ^b   Tsai, Michael Y ^c   Heckbert, Susan R ^d   Aleksic, Nena ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Prospective study; Prothrombin; Pulmonary embolus; Venous thrombosis

Indexed keywords

PROTHROMBIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; THROMBOEMBOLISM; UNITED STATES; VEIN THROMBOSIS;

EID: 0036891940     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10229     Document Type: Article

References (40)

1. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A protbrombin variant. Thromb Haemost 1998;79:706-708.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
3. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-1433.
4. Hillarp A, Zoller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997;78:990-992.
5. Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol 1997;17:2875-2879.
6. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-2422.
7. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997;78:1426-1429.
8. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997;99:304-307.
9. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: Prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997;98:353-355.
10. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997;98:907-909.
11. 20210 gene variant. Ann Intern Med 1998;129:89-93.
12. Souto JC, Coll I, Llobet D, del Rio E, Oliver A, Mateo J, Borrell M, Fontcuberta J. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998;80:366-369.
13. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998;80:49-51.
14. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: Prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999;82:1395-1398.
15. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 1999;93:1-8.
16. Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999;81:506-510.
17. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999;81:733-738.
18. Adamczuk Y, Iglesias Varela ML, Forastiero R, Martinuzzo M, Cerrato G, Pombo G, Carreras LO. Factor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population [letter]. Thromb Haemost 2000;83:509-510.
19. Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 2000;75:595-604.
20. Girolami A, Vianello F. The significance or nonsignificance of the G to A 20210 prothrombin polymorphism [letter]. Clin Appl Thromb/Hemost 2000;6:239-240.
21. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-806.
22. Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, del Popolo A, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-1587.
23. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H, DURAC Trial Study Group, Duration of anticoagulation. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999;81:684-689.
24. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stumpflen A, Schneider B, Lechner K, Kyrle PA. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999;81:14-17.
25. Simioni P, Prandoni P, Lensing AWA, Manfrin D, Tormene D, Gavasso S, Girolami B, Sardella C, Prins M, Girolami A. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deepvein thrombosis. Blood 2000;96:3329-3333.
26. Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001;37:215-218.
27. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999;99:9991004.
28. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The Longitudinal Investigation of Thromboembolism Etiology (LITE) study. Arch Intern Med 2002;162:1182-1189.
29. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002;99:2720-2725.
30. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:1102-1108.
31. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264-270.
32. Rothman KJ, Greenland S. Modem Epidemiology. Philadelphia, PA: Lippincott-Raven Publishers; 1998. p 97-98.
33. Smiles AM, Macy EM, Sakkinen PA, Bovill EG, Mann KG, Tracy RP. Variability in plasma prothrombin concentration: Implications for use in epidemiology. Blood Coagulation Fibrinol 1998;9:525-531.
34. de Ronde H, Bertina R. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72:880-886.
35. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Cancrum 1953;9:531-541.
36. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619.
37. Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998;103:1045-1050.
38. von Ahsen N, Lewczuk P, Schutz E, Oellerich M, Ehrenreich H. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. Thromb Res 2000;99:549-556.
39. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J, Fontcuberta J. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000;95:2780-2785.
40. Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, Zaia B, Mazzucco A, Corrocher R. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 2001;103:2436-2440.